SCHEMBL5158958

SCHEMBL5158958

COC(=O)COc1cc2ccccc2c2c1cc(C)n2CC1CCCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 2/20 0.66
ALDH1A1 P00352 7/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 2/20 0.43
HSD17B10 Q99714 1/20 0.43
PTGDR Q13258 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PLA2G1B P04054 3/20 0.40
NPSR1 Q6W5P4 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NUAK1 O60285 1/20 0.38
JAK2 O60674 1/20 0.38
NTRK1 P04629 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
FLT3 P36888 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5162888 0.84 PLA2G2A (0.48) PLA2G2AALDH1A1HPGDKDM4EPOLB
SCHEMBL5159820 0.80 PLA2G2A (1.00) PLA2G2APLA2G1B
SCHEMBL5159760 0.74 KMT2A (0.49) PLA2G2AALDH1A1HSD17B10HTTPLA2G1B
SCHEMBL14608292 0.73 ALDH1A1 (0.44) PLA2G2AALDH1A1KDM4EPLA2G1BJAK2
SCHEMBL5159835 0.72 PLA2G2A (0.46) PLA2G2AALDH1A1HTTPLA2G1BNPSR1
SCHEMBL5160095 0.71 PLA2G2A (0.52) PLA2G2AALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL5157692 0.71 PLA2G2A (1.00) PLA2G2APLA2G1B
SCHEMBL5160764 0.70 PLA2G2A (0.41) PLA2G2AALDH1A1HPGDKDM4EPOLB
SCHEMBL14608479 0.69 PLA2G2A (0.87) PLA2G2APLA2G1B
SCHEMBL15426819 0.68 HTT (0.67) ALDH1A1HPGDKDM4EPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
US-6916840-B2 Spla2 inhibitors ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-20040063967-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063967-A1 Novel spla2 inhibitors PLA2G12A, SPINT2, PLA2G4A PLA2G2A 16/4885ALDH1A1 2761/4885HPGD 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.